Selected Start-Ups Founded in 2000 (03/00)
Executive Summary
{In Vivo} summarizes the technologies of several recently founded companies: Netherlands start-up [BioMaDe BV] will use nanotechnology to design and construct molecular devices for use in a variety of commercial applications. [DirectGene Inc.] is developing a tissue specific gene promoter technology for cancer gene therapy, based on the role of tumor-stromal interactions. [Esurg.com] will sell medical, surgical and pharmaceutical supplies and information to out-of-hospital healthcare providers. Founded in June 1999, [ImmunoGenec Biotechnologie GmbH] aims to develop, produce and market protein-based therapies for the immunotherapeutic treatment of certain cancers. [Quorex Pharmaceuticals Inc.] will discover anti-infectives using its discovery of a novel signaling pathway that occurs in wide variety of pathogenic bacteria. A joint venture of Rohm & Haas Co. and Argonex Inc, [RHeoGene LLC.] is developing enabling gene tools based on its proprietary Ecdyosyne Recepter-based gene switch system.
You may also be interested in...
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
Betahistine Leads A Raft Of UK Rises In August
With multiple generic molecules experiencing treble-digit-percentage price increases in the UK in August, betahistine tablets led the month’s biggest risers, according to WaveData.
Biocon Gets A New Group CEO As Aflibercept Approval Arrives
Biocon has named Peter Bains as its new group CEO, as the firm’s Biocon Biologics business confirmed that its aflibercept biosimilar to Eylea had become the first to receive a formal European approval.